Welcome to our dedicated page for KORU Medical Systems SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
Thomas Edward Adams, Chief Financial Officer of KORU Medical Systems (KRMD), received equity awards under the company’s 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program. The grants include 32,773 restricted stock units that vest one-fourth on May 12, 2026 and annually thereafter, 32,773 performance-based restricted stock units payable at target (the Reporting Person could earn 0%-150% of the reported amount, further multiplied by between 0.5 to 1.5) based on performance as of December 31, 2027 and vesting at 100% on a change in control prior to that date, and an option to purchase 55,583 shares with a stated exercise price of $3.21 that vests one-fourth on May 12, 2026 and annually thereafter. Each reported position is listed as direct ownership.
KORU Medical Systems insider award summary: Adam R. Kalbermatten, the company’s Chief Commercial Officer, received a 300,000-share restricted stock award as an employment inducement and an option to buy 600,000 shares. The restricted shares vest 25% annually beginning July 28, 2026, subject to acceleration under his employment agreement. The option carries a $3.44 exercise price, a listed expiration of August 1, 2035, and a vesting schedule of one-fourth on August 1, 2026 and on each anniversary thereafter for three years.
What this means: The grants align compensation with future service and performance but create potential dilution of up to 900,000 shares if fully issued and exercised. Both holdings are reported as directly owned by the reporting person.
KORU Medical Systems, Inc. filed an initial insider ownership report for its Chief Commercial Officer, Adam R. Kalbermatten. The Form 3 shows that, as of the event date of 07/28/2025, he beneficially owned 0 shares of KORU Medical common stock in direct ownership. This filing establishes his baseline reported ownership as a newly reported officer of the company.